. Author manuscript; available in PMC: 2014 Mar 26.

Published in final edited form as: Int J Tuberc Lung Dis. 2013 Sep;17(9):1125–1138. doi: 10.5588/ijtld.13.0117

Table 3.

Use of Xpert® MTB/RIF for screening

			HIV prevalence		Culture-positive n	Sensitivity of smear microscopy % (95%CI)	Sensitivity of Xpert® MTB/RIF % (95%CI)
Study	Country	Screening population	% positive	n	Culture-positive n	Sensitivity of smear microscopy % (95%CI)	Sensitivity of Xpert® MTB/RIF % (95%CI)
Lawn, 2012⁵²	South Africa	ART clinic	100	515	81	22.2 (13.3–33.6)	58.3 (46.1–69.8)
O’Grady, 2012⁹	Zambia	Medical admissions able to produce sputum	65	881	201	52.8 (45.1–60.4): HIV+ 48.6 (33.0–64.4): HIV−	88.2 (81.9–92.6): HIV− 74.3 (56.4–87.0): HIV−
Dorman, 2012⁴⁹	South Africa	Prevalence survey	ND	6893	187	17.6 (12.5–23.9): HIV+	62.6 (55.2–69.5)
Ntinginya 2012⁵¹	Tanzania	Household contacts	ND	219	5	60.0 (14.7–94.7): HIV−	100 (47.8–100)

HIV = human immunodeficiency virus; ART = antiretroviral therapy; ND = not done.